Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 2
1(20.0%)
5Total
N/A(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05880472Not ApplicableActive Not Recruiting

Percutaneous Holmium Injection in Pancreatic Cancer

Role: collaborator

NCT05191498Not ApplicableCompleted

Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer

Role: collaborator

NCT03379844Phase 2Completed

HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients

Role: collaborator

NCT04269499Not ApplicableCompleted

Real-time Imaging of Holmium Radioembolization: a Feasibility Study

Role: collaborator

NCT03437382Not ApplicableCompleted

Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study

Role: collaborator

All 5 trials loaded